Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Strides’ Founder Considering Stake Sale In UK CDMO?

Executive Summary

More M&A may be in store in the contract development and manufacturing space, with the founder of India’s Strides group apparently open to divesting his holding in the UK-based Sterling Pharma Solutions, at least going by what some deal street insiders say.

You may also be interested in...



Key Trends In CDMO Space As Dissected By Piramal Pharma Solutions CEO

Piramal Pharma Solutions CEO Vivek Sharma discusses a range of issues shaping the buzzing contract development and manufacturing segment in an interview with Scrip. Heightened consolidation and attractive prospects in the area of antibody drug conjugates, where over 600 clinical trials are being conducted worldwide, are some of the trends to watch out for.

CDMO Space In Focus As Piramal Mulls Sale

As the Indian business conglomerate Piramal considers the sale of its contract development and manufacturing organization (CDMO), some experts say that more CDMO players could potentially join the sale line up in a fragmented sector but one that’s in demand.

Strides’ Founder Resumes Charge After Dismal Q4 Earnings

Strides Shasun founder Arun Kumar has moved back into the driver’s seat to focus on “course correction” after the Indian drug maker racked up an unexpected quarterly loss that triggered a massive share selloff.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC124192

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel